Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023 10:08 ET
|
Vivos Inc.
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy...
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
January 11, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision...
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
January 03, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision...
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™
September 14, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA...
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy
August 16, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer...